Hospital
United Health Services Hospitals, INC.
United Health Services Hospitals, INC. was paid $163.20M by Medicaid between Jan 2018 and Dec 2024, across 661 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 16% of everything it billed.
33Billing provider infoUNITED HEALTH SERVICES HOSPITALS, INC.
BINGHAMTON, NY 13903
BINGHAMTON, NY 13903
33aNPI1518998699assigned 07/06/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$163.20M
24GClaims2,757,807
24DCodes billed661
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in New York
Rank by total paid#9 of 231
Median peer was paid$561K
This provider vs. median291×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 26,052 | $756K | |
| 2019 | 143,054 | $6.96M | |
| 2020 | 401,418 | $22.65M | |
| 2021 | 539,645 | $30.47M | |
| 2022 | 571,789 | $33.36M | |
| 2023 | 605,108 | $37.32M | |
| 2024incomplete | 470,741 | $31.69M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 16% | 230,686 | 203,467 | $25.93M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 9.7% | 140,567 | 126,278 | $15.79M |
| 90791 | Psychiatric diagnostic evaluationPsychiatric diagnostic evaluation | 3.9% | 10,591 | 9,649 | $6.45M |
| H0020 | Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program) | 3.1% | 182,040 | 11,690 | $4.99M |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.8% | 18,739 | 15,620 | $4.53M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 2.7% | 28,774 | 27,064 | $4.33M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.5% | 26,551 | 24,421 | $4.12M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 2.2% | 23,074 | 21,142 | $3.63M |
| G2067 | Medication assisted treatment, methadone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing, if performed (provision of the services by a medicare-enrolled opioid treatment program) | 2.0% | 15,785 | 4,590 | $3.29M |
| 90832 | Psychotherapy session, about 30 minutesPsychotherapy, 30 minutes with patient | 1.8% | 26,044 | 17,894 | $2.89M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.7% | 52,397 | 16,408 | $2.72M |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 1.7% | 23,546 | 23,353 | $2.70M |
649 more codes
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.6% | 35,485 | $2.68M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.6% | 7,748 | $2.63M |
| 80053 | Comprehensive metabolic panel | 1.5% | 117,321 | $2.45M |
| 70450 | Computed tomography, head or brain; without contrast material | 1.4% | 7,820 | $2.33M |
| G9005 | Coordinated care fee, risk adjusted maintenance | 1.3% | 7,239 | $2.07M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.2% | 2,766 | $2.03M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.2% | 12,938 | $1.95M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.1% | 15,957 | $1.82M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 1.0% | 14,747 | $1.67M |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 1.0% | 14,112 | $1.64M |
| 59025 | Fetal non-stress test | <1% | 10,228 | $1.60M |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 13,404 | $1.56M |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 11,372 | $1.54M |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 12,766 | $1.50M |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 12,259 | $1.41M |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 29,096 | $1.25M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 3,642 | $1.21M |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 10,219 | $1.17M |
| H0005 | Alcohol and/or drug services; group counseling by a clinician | <1% | 19,023 | $1.17M |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 1,381 | $1.07M |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 8,926 | $1.05M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 23,190 | $1.03M |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 4,590 | $921K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 34,618 | $890K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 5,763 | $890K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 18,966 | $855K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 18,870 | $838K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 2,792 | $792K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 1,084 | $773K |
| H0001 | Alcohol and/or drug assessment | <1% | 4,931 | $747K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 2,041 | $724K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 5,250 | $697K |
| H0004 | Behavioral health counseling and therapy, per 15 minutes | <1% | 13,827 | $678K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 5,771 | $662K |
| J9271 | Injection, pembrolizumab, 1 mg | <1% | 76 | $641K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 20,101 | $641K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 5,380 | $628K |
| 97161 | <1% | 6,670 | $618K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 3,912 | $589K |
| 20610 | <1% | 2,209 | $542K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 3,452 | $498K |
| 93970 | <1% | 1,069 | $494K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 6,517 | $492K |
| 12001 | <1% | 1,109 | $473K | |
| 90686 | <1% | 21,637 | $456K | |
| 76770 | <1% | 1,674 | $442K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 20,112 | $425K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 3,296 | $422K |
| S9480 | Intensive outpatient psychiatric services, per diem | <1% | 3,612 | $413K |
| 80061 | Lipid panel | <1% | 27,723 | $408K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 26,634 | $407K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 5,293 | $400K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 13,645 | $400K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 3,423 | $395K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 8,439 | $385K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 13,493 | $381K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 427 | $381K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 34,498 | $378K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 13,209 | $378K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 5,406 | $373K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 2,761 | $366K |
| 76830 | Ultrasound, transvaginal | <1% | 5,072 | $356K |
| 17110 | <1% | 1,350 | $348K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 6,217 | $340K |
| 86900 | <1% | 9,731 | $336K | |
| 87631 | <1% | 5,006 | $326K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 677 | $325K |
| H0037 | Community psychiatric supportive treatment program, per diem | <1% | 297 | $321K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 3,220 | $311K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 7,955 | $303K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 5,348 | $280K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,140 | $276K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 12,008 | $276K |
| 96415 | <1% | 780 | $272K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,417 | $270K |
| 90715 | <1% | 9,499 | $246K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 8,268 | $243K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 82,516 | $223K |
| 90837 | Psychotherapy session, about an hour | <1% | 1,716 | $219K |
| 72131 | <1% | 977 | $217K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 3,051 | $216K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 767 | $212K |
| 36415 | Collection of venous blood by venipuncture | <1% | 42,923 | $208K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 294 | $207K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 551 | $202K |
| 90648 | <1% | 10,242 | $202K | |
| 90750 | <1% | 1,415 | $199K | |
| 90651 | <1% | 4,620 | $198K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 9,734 | $196K |
| 86850 | <1% | 9,349 | $194K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,971 | $192K |
| 99385 | <1% | 1,617 | $187K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 11,507 | $180K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 2,790 | $177K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 603 | $173K |
| 90723 | <1% | 8,342 | $168K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 2,301 | $164K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 4,460 | $163K |
| 20611 | <1% | 374 | $157K | |
| 92567 | <1% | 2,256 | $155K | |
| 87486 | <1% | 3,673 | $149K | |
| 90680 | <1% | 7,407 | $149K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 526 | $147K |
| 70491 | <1% | 529 | $145K | |
| 64493 | <1% | 207 | $145K | |
| 86480 | <1% | 2,520 | $144K | |
| 86901 | <1% | 9,775 | $135K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 20,895 | $132K |
| 90670 | <1% | 6,764 | $129K | |
| G0382 | Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 834 | $129K |
| 99381 | <1% | 1,110 | $128K | |
| 84702 | <1% | 13,660 | $127K | |
| 12011 | <1% | 282 | $126K | |
| J3490 | Unclassified drugs | <1% | 2,374 | $124K |
| 99205 | Prolong outpt/office vis | <1% | 1,065 | $123K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,654 | $123K |
| 83880 | <1% | 3,611 | $122K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 691 | $122K |
| 90734 | <1% | 5,554 | $122K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 71 | $119K |
| G0378 | Hospital observation service, per hour | <1% | 3,333 | $118K |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 3,263 | $117K |
| 90633 | <1% | 5,905 | $117K | |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 1,842 | $116K |
| 90677 | <1% | 3,303 | $116K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 8,689 | $115K |
| 97165 | <1% | 1,375 | $115K | |
| G0381 | Level 2 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 725 | $115K |
| 87536 | <1% | 1,364 | $113K | |
| 93971 | <1% | 1,463 | $112K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 247 | $111K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 9,258 | $111K |
| J3380 | Injection, vedolizumab, intravenous, 1 mg | <1% | 26 | $110K |
| 96367 | <1% | 1,860 | $105K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 12,243 | $104K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 5,424 | $103K |
| 76641 | <1% | 1,799 | $103K | |
| H0033 | Oral medication administration, direct observation | <1% | 3,923 | $103K |
| D1110 | Prophylaxis - adult | <1% | 1,997 | $101K |
| 97162 | <1% | 834 | $101K | |
| 77066 | Tomosynthesis, mammo | <1% | 1,205 | $101K |
| 84439 | <1% | 13,578 | $101K | |
| 73221 | <1% | 365 | $98K | |
| 76536 | <1% | 1,872 | $98K | |
| 81003 | <1% | 58,280 | $98K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 5,311 | $97K |
| 71250 | <1% | 1,168 | $97K | |
| 51798 | <1% | 332 | $97K | |
| 76942 | <1% | 483 | $96K | |
| 76820 | <1% | 2,471 | $94K | |
| 99383 | <1% | 794 | $94K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,286 | $93K |
| J0592 | Injection, buprenorphine hydrochloride, 0.1 mg | <1% | 6,011 | $93K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 401 | $93K |
| 92557 | <1% | 1,551 | $92K | |
| 72141 | <1% | 356 | $92K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 20,038 | $91K |
| 88342 | <1% | 1,540 | $90K | |
| 87522 | Neg quan hep c or qual rna | <1% | 2,253 | $89K |
| 77065 | Tomosynthesis, mammo | <1% | 1,014 | $88K |
| 12002 | <1% | 191 | $87K | |
| 83655 | <1% | 6,929 | $86K | |
| 99386 | <1% | 739 | $86K | |
| 93880 | <1% | 261 | $82K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 46 | $82K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 8,721 | $80K |
| 87581 | <1% | 3,675 | $80K | |
| 97116 | <1% | 2,451 | $79K | |
| 93017 | <1% | 912 | $78K | |
| 85610 | <1% | 19,698 | $78K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 21,642 | $77K |
| 81025 | <1% | 16,881 | $76K | |
| 70486 | <1% | 942 | $75K | |
| 86803 | <1% | 8,263 | $74K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 4,363 | $74K |
| G2078 | Take-home supply of methadone; up to 7 additional day supply (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure | <1% | 1,751 | $72K |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 97 | $71K |
| Q5103 | Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | <1% | 87 | $71K |
| 87390 | <1% | 2,856 | $70K | |
| 87634 | <1% | 1,508 | $67K | |
| 80329 | <1% | 928 | $67K | |
| 58300 | <1% | 438 | $67K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 402 | $67K |
| 20550 | <1% | 275 | $65K | |
| 90710 | <1% | 3,195 | $64K | |
| 83970 | <1% | 1,698 | $63K | |
| 76642 | <1% | 1,258 | $62K | |
| J7298 | Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg | <1% | 96 | $61K |
| 19083 | <1% | 37 | $60K | |
| 90707 | <1% | 2,850 | $59K | |
| 36416 | <1% | 3,973 | $58K | |
| 90716 | <1% | 2,715 | $57K | |
| 86360 | <1% | 1,353 | $55K | |
| 90696 | <1% | 2,783 | $55K | |
| 92587 | <1% | 795 | $55K | |
| 58100 | <1% | 128 | $54K | |
| 90700 | <1% | 2,703 | $54K | |
| 88307 | <1% | 454 | $53K | |
| 10060 | <1% | 180 | $52K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 162 | $52K |
| 88304 | <1% | 1,319 | $52K | |
| 99384 | <1% | 442 | $52K | |
| 93225 | <1% | 495 | $52K | |
| 94060 | <1% | 375 | $51K | |
| 90656 | <1% | 2,533 | $50K | |
| J1726 | Injection, hydroxyprogesterone caproate, (makena), 10 mg | <1% | 96 | $50K |
| D0140 | Limited oral evaluation - problem focused | <1% | 2,297 | $49K |
| G0380 | Level 1 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 280 | $49K |
| 87340 | <1% | 6,362 | $49K | |
| 82607 | <1% | 4,815 | $49K | |
| 73110 | <1% | 2,744 | $49K | |
| S9484 | Crisis intervention mental health services, per hour | <1% | 99 | $48K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,147 | $48K |
| 87070 | <1% | 14,151 | $47K | |
| 29125 | <1% | 225 | $47K | |
| 85027 | <1% | 12,404 | $45K | |
| 84403 | <1% | 1,959 | $45K | |
| 95816 | <1% | 253 | $44K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 45 | $43K |
| S9485 | Crisis intervention mental health services, per diem | <1% | 30 | $41K |
| 82728 | <1% | 4,294 | $41K | |
| 98968 | <1% | 366 | $41K | |
| 82670 | <1% | 1,612 | $40K | |
| 72100 | <1% | 1,258 | $38K | |
| 86762 | <1% | 4,060 | $37K | |
| 98967 | <1% | 324 | $36K | |
| C1763 | Connective tissue, non-human (includes synthetic) | <1% | 33 | $36K |
| 73630 | <1% | 3,503 | $35K | |
| 87625 | <1% | 1,213 | $34K | |
| 90671 | <1% | 1,609 | $34K | |
| 86140 | <1% | 21,208 | $34K | |
| 99382 | <1% | 299 | $33K | |
| 84146 | <1% | 1,953 | $32K | |
| 86592 | <1% | 8,506 | $32K | |
| 82803 | <1% | 957 | $32K | |
| 73564 | <1% | 2,094 | $32K | |
| 57454 | <1% | 71 | $32K | |
| H0038 | Self-help/peer services, per 15 minutes | <1% | 851 | $31K |
| 72110 | <1% | 798 | $31K | |
| 70498 | <1% | 84 | $31K | |
| 84153 | <1% | 2,102 | $31K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 5,263 | $30K |
| 86357 | <1% | 1,316 | $30K | |
| 86359 | <1% | 1,314 | $30K | |
| 76870 | <1% | 449 | $30K | |
| 86355 | <1% | 1,313 | $30K | |
| 71271 | <1% | 513 | $29K | |
| 98966 | <1% | 244 | $29K | |
| 84144 | <1% | 1,531 | $28K | |
| 87529 | <1% | 679 | $28K | |
| 73130 | <1% | 2,408 | $28K | |
| 82570 | <1% | 6,462 | $28K | |
| G9001 | Coordinated care fee, initial rate | <1% | 373 | $28K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,393 | $28K |
| 76801 | <1% | 358 | $28K | |
| 83001 | <1% | 1,692 | $27K | |
| 84402 | <1% | 1,197 | $27K | |
| 77080 | <1% | 386 | $27K | |
| 86618 | <1% | 2,636 | $27K | |
| D0330 | Panoramic radiographic image | <1% | 688 | $27K |
| 86787 | <1% | 4,439 | $26K | |
| 73610 | <1% | 2,727 | $26K | |
| 82043 | <1% | 5,523 | $26K | |
| 97760 | <1% | 681 | $25K | |
| 88341 | <1% | 528 | $25K | |
| 97014 | <1% | 1,248 | $24K | |
| 93458 | <1% | 14 | $24K | |
| 58661 | <1% | 13 | $24K | |
| 92526 | <1% | 214 | $23K | |
| 73030 | <1% | 2,354 | $23K | |
| 72040 | <1% | 926 | $23K | |
| 71045 | Radiologic examination, chest; single view | <1% | 7,592 | $23K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 9,661 | $23K |
| 85018 | <1% | 2,587 | $22K | |
| 97035 | <1% | 1,527 | $21K | |
| 81511 | <1% | 257 | $21K | |
| 86003 | <1% | 644 | $21K | |
| 82784 | <1% | 2,207 | $21K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 172 | $21K |
| H0002 | Behavioral health screening to determine eligibility for admission to treatment program | <1% | 125 | $21K |
| 87902 | <1% | 76 | $20K | |
| 73502 | <1% | 1,328 | $20K | |
| 86706 | <1% | 2,405 | $19K | |
| 94726 | <1% | 361 | $19K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 171 | $19K |
| 80361 | <1% | 1,016 | $18K | |
| 83002 | <1% | 1,114 | $18K | |
| 80076 | <1% | 1,546 | $18K | |
| 80050 | General health panel | <1% | 440 | $18K |
| 87077 | <1% | 4,857 | $18K | |
| 74018 | <1% | 1,165 | $18K | |
| 86580 | <1% | 1,930 | $18K | |
| 64483 | <1% | 24 | $17K | |
| 90620 | <1% | 639 | $17K | |
| 11102 | <1% | 40 | $17K | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 273 | $17K |
| H2011 | Crisis intervention service, per 15 minutes | <1% | 111 | $17K |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 329 | $17K |
| 11981 | <1% | 69 | $17K | |
| 83550 | <1% | 3,446 | $17K | |
| 93226 | <1% | 311 | $16K | |
| 73140 | <1% | 1,410 | $16K | |
| 80069 | <1% | 1,450 | $16K | |
| 86039 | <1% | 2,844 | $16K | |
| 86160 | <1% | 1,075 | $16K | |
| 58301 | <1% | 117 | $16K | |
| 87186 | <1% | 4,726 | $16K | |
| 83540 | <1% | 3,855 | $16K | |
| 11721 | <1% | 358 | $16K | |
| 80320 | <1% | 1,704 | $16K | |
| 82950 | <1% | 2,970 | $15K | |
| 87081 | <1% | 4,280 | $15K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 233 | $15K |
| 69210 | <1% | 149 | $15K | |
| 0001A | <1% | 381 | $15K | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 1,175 | $15K |
| 52000 | <1% | 12 | $15K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 68 | $15K |
| 43248 | <1% | 31 | $14K | |
| 86703 | <1% | 1,199 | $14K | |
| 87205 | <1% | 8,866 | $14K | |
| 0002A | <1% | 347 | $14K | |
| 82746 | <1% | 1,392 | $14K | |
| 77336 | <1% | 53 | $14K | |
| 72082 | <1% | 293 | $14K | |
| 99442 | <1% | 136 | $14K | |
| 86235 | <1% | 1,026 | $13K | |
| 84480 | <1% | 1,796 | $13K | |
| 85652 | <1% | 8,799 | $13K | |
| 83735 | <1% | 9,614 | $13K | |
| 85730 | <1% | 9,609 | $13K | |
| 0071A | <1% | 335 | $13K | |
| 51702 | <1% | 38 | $13K | |
| 73560 | <1% | 1,041 | $13K | |
| 86376 | <1% | 1,102 | $12K | |
| 0012A | <1% | 375 | $12K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 6,232 | $12K |
| 11104 | <1% | 25 | $12K | |
| 82105 | <1% | 1,365 | $12K | |
| 83021 | <1% | 1,086 | $12K | |
| 11750 | <1% | 26 | $12K | |
| 36600 | <1% | 411 | $12K | |
| 93242 | <1% | 134 | $12K | |
| 90732 | <1% | 299 | $12K | |
| 96127 | <1% | 3,979 | $12K | |
| 0225U | <1% | 677 | $11K | |
| 0072A | <1% | 290 | $11K | |
| D0120 | Dental checkup, returning patient | <1% | 409 | $11K |
| 0011A | <1% | 433 | $11K | |
| D0220 | Intraoral - periapical first radiographic image | <1% | 815 | $11K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 350 | $11K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 71 | $10K |
| 90682 | <1% | 416 | $10K | |
| 86765 | <1% | 981 | $10K | |
| 99050 | <1% | 1,151 | $10K | |
| 92579 | <1% | 162 | $9K | |
| 73590 | <1% | 765 | $9K | |
| 74183 | <1% | 25 | $9K | |
| 36430 | <1% | 37 | $9K | |
| 75574 | <1% | 67 | $9K | |
| 97802 | <1% | 219 | $9K | |
| 91322 | <1% | 285 | $9K | |
| 64635 | <1% | 14 | $9K | |
| T1023 | Screening to determine the appropriateness of consideration of an individual for participation in a specified program, project or treatment protocol, per encounter | <1% | 153 | $8K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 1,040 | $8K |
| 73090 | <1% | 506 | $8K | |
| D1120 | Dental cleaning, child | <1% | 194 | $8K |
| 83020 | <1% | 1,087 | $8K | |
| 86364 | <1% | 1,079 | $8K | |
| 86431 | <1% | 1,765 | $8K | |
| A9573 | Injection, gadopiclenol, 1 ml | <1% | 381 | $7K |
| 86800 | <1% | 637 | $7K | |
| 84481 | <1% | 700 | $7K | |
| 90739 | <1% | 150 | $7K | |
| 86735 | <1% | 815 | $7K | |
| 80159 | <1% | 544 | $7K | |
| 86665 | <1% | 275 | $6K | |
| 86666 | <1% | 547 | $6K | |
| 73080 | <1% | 612 | $6K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 18 | $6K |
| 84550 | <1% | 2,224 | $6K | |
| 87040 | <1% | 3,185 | $6K | |
| 82533 | <1% | 921 | $6K | |
| 82248 | <1% | 1,404 | $6K | |
| 97016 | <1% | 340 | $6K | |
| 94729 | <1% | 362 | $6K | |
| 80164 | <1% | 488 | $6K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,703 | $6K |
| 83690 | <1% | 10,935 | $6K | |
| 86704 | <1% | 703 | $6K | |
| 80178 | <1% | 891 | $6K | |
| 86708 | <1% | 638 | $6K | |
| 74019 | <1% | 290 | $5K | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 213 | $5K |
| 93798 | <1% | 188 | $5K | |
| 73562 | <1% | 600 | $5K | |
| 88185 | <1% | 44 | $5K | |
| 76825 | <1% | 26 | $5K | |
| 99051 | <1% | 595 | $5K | |
| 83615 | <1% | 1,684 | $5K | |
| 82627 | <1% | 248 | $5K | |
| 86753 | <1% | 449 | $5K | |
| 0003A | <1% | 138 | $5K | |
| 90714 | <1% | 178 | $5K | |
| 84100 | <1% | 1,649 | $5K | |
| 90678 | <1% | 75 | $5K | |
| 86696 | <1% | 422 | $5K | |
| 82962 | <1% | 7,108 | $5K | |
| 82550 | <1% | 6,579 | $4K | |
| 76882 | <1% | 79 | $4K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 69 | $4K |
| 80358 | <1% | 857 | $4K | |
| 83721 | <1% | 858 | $4K | |
| 91200 | <1% | 64 | $4K | |
| J0574 | Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphine | <1% | 604 | $4K |
| 95886 | <1% | 63 | $4K | |
| 86617 | <1% | 371 | $4K | |
| 74174 | <1% | 12 | $4K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 493 | $4K |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 34 | $4K |
| 0064A | <1% | 101 | $4K | |
| 84484 | <1% | 10,379 | $4K | |
| 85014 | <1% | 1,691 | $4K | |
| 86225 | <1% | 622 | $4K | |
| 84156 | <1% | 1,439 | $4K | |
| 92588 | <1% | 63 | $4K | |
| 87147 | <1% | 2,405 | $4K | |
| 99441 | <1% | 58 | $4K | |
| 82565 | <1% | 1,002 | $4K | |
| 84436 | <1% | 1,282 | $4K | |
| 83516 | <1% | 629 | $4K | |
| 31575 | <1% | 47 | $4K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 2,527 | $4K |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 713 | $4K |
| 82150 | <1% | 3,415 | $3K | |
| 97803 | <1% | 101 | $3K | |
| 80365 | <1% | 548 | $3K | |
| 87806 | <1% | 183 | $3K | |
| 29405 | <1% | 14 | $3K | |
| 99443 | <1% | 49 | $3K | |
| 86709 | <1% | 488 | $3K | |
| 0051A | <1% | 87 | $3K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 214 | $3K |
| G0476 | Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test | <1% | 99 | $3K |
| 87506 | <1% | 28 | $3K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 274 | $3K |
| 90480 | <1% | 281 | $3K | |
| 80362 | <1% | 255 | $3K | |
| 80350 | <1% | 253 | $3K | |
| 85379 | <1% | 2,987 | $3K | |
| 88108 | <1% | 43 | $3K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 39 | $3K |
| 72128 | <1% | 13 | $3K | |
| 81596 | <1% | 44 | $3K | |
| 29515 | <1% | 12 | $3K | |
| 73700 | <1% | 13 | $2K | |
| 84112 | <1% | 55 | $2K | |
| 86664 | <1% | 216 | $2K | |
| 90713 | <1% | 111 | $2K | |
| 80356 | <1% | 476 | $2K | |
| 82947 | <1% | 372 | $2K | |
| 80346 | <1% | 472 | $2K | |
| 90381 | <1% | 89 | $2K | |
| 80348 | <1% | 455 | $2K | |
| 82247 | <1% | 582 | $2K | |
| G0008 | Administration of influenza virus vaccine | <1% | 245 | $2K |
| 80353 | <1% | 477 | $2K | |
| 86920 | <1% | 39 | $2K | |
| 90694 | <1% | 185 | $2K | |
| 0031A | <1% | 58 | $2K | |
| D1208 | Topical application of fluoride, excluding varnish | <1% | 150 | $2K |
| 90380 | <1% | 80 | $2K | |
| 74178 | <1% | 12 | $2K | |
| J0185 | Injection, aprepitant, 1 mg | <1% | 18 | $2K |
| 87468 | <1% | 83 | $2K | |
| 87484 | <1% | 83 | $2K | |
| 87469 | <1% | 81 | $2K | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 16 | $2K |
| 86769 | <1% | 49 | $2K | |
| 88184 | <1% | 27 | $2K | |
| 90744 | <1% | 80 | $2K | |
| 99401 | <1% | 38 | $2K | |
| D0274 | Bitewings - four radiographic images | <1% | 44 | $2K |
| 94799 | <1% | 27 | $2K | |
| 83993 | <1% | 126 | $2K | |
| 95909 | <1% | 13 | $2K | |
| 84520 | <1% | 461 | $1K | |
| 73620 | <1% | 176 | $1K | |
| 99454 | <1% | 14 | $1K | |
| 97010 | <1% | 114 | $1K | |
| 91321 | <1% | 56 | $1K | |
| 82553 | <1% | 40 | $1K | |
| 86308 | <1% | 961 | $1K | |
| 85576 | <1% | 63 | $1K | |
| 83525 | <1% | 125 | $1K | |
| 96411 | <1% | 58 | $1K | |
| 86870 | <1% | 14 | $1K | |
| 82951 | <1% | 126 | $1K | |
| 90636 | <1% | 19 | $1K | |
| 80325 | <1% | 237 | $1K | |
| 80306 | <1% | 148 | $1K | |
| 72072 | <1% | 51 | $1K | |
| 80349 | <1% | 232 | $1K | |
| Q9950 | Injection, sulfur hexafluoride lipid microspheres, per ml | <1% | 56 | $1K |
| 99406 | <1% | 25 | $1K | |
| 72050 | <1% | 51 | $1K | |
| 73120 | <1% | 78 | $1K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,689 | $942.03 |
| 90679 | <1% | 24 | $917.82 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 15,064 | $917.58 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 687 | $917.22 |
| 86923 | <1% | 12 | $907.32 | |
| 90685 | <1% | 52 | $900.00 | |
| 83605 | <1% | 3,136 | $881.43 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 409 | $836.18 |
| 99152 | <1% | 131 | $807.92 | |
| 72170 | <1% | 114 | $789.61 | |
| 87478 | <1% | 33 | $745.11 | |
| 96376 | <1% | 2,632 | $734.79 | |
| 70496 | <1% | 13 | $703.64 | |
| 87210 | <1% | 832 | $696.59 | |
| 96523 | <1% | 16 | $694.44 | |
| 72114 | <1% | 27 | $690.37 | |
| 87476 | <1% | 32 | $676.68 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,757 | $668.93 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 2,004 | $667.74 |
| 86705 | <1% | 92 | $637.31 | |
| 86200 | <1% | 88 | $565.39 | |
| 80324 | <1% | 111 | $563.97 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 77 | $560.29 |
| 84165 | <1% | 79 | $546.12 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 27 | $542.07 |
| 73000 | <1% | 27 | $541.20 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 7,772 | $525.38 |
| 96417 | <1% | 159 | $522.02 | |
| 92555 | <1% | 15 | $500.80 | |
| 80345 | <1% | 77 | $476.32 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 6,572 | $474.78 |
| 82378 | <1% | 82 | $461.32 | |
| 80323 | <1% | 88 | $459.94 | |
| 94760 | <1% | 389 | $459.86 | |
| 86255 | <1% | 66 | $428.72 | |
| 73660 | <1% | 12 | $404.38 | |
| 73521 | <1% | 13 | $391.88 | |
| 94664 | <1% | 241 | $369.10 | |
| D1206 | Topical application of fluoride varnish | <1% | 12 | $360.00 |
| 90632 | <1% | 12 | $331.08 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 900 | $328.72 |
| 86780 | <1% | 27 | $327.65 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 9,657 | $326.76 |
| 99000 | <1% | 17 | $321.64 | |
| 80354 | <1% | 30 | $312.06 | |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | <1% | 13 | $309.94 |
| 73070 | <1% | 15 | $297.68 | |
| C1769 | Guide wire | <1% | 658 | $279.54 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 10,278 | $279.22 |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 536 | $272.29 |
| 83521 | <1% | 21 | $241.47 | |
| 80359 | <1% | 43 | $218.45 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 7,010 | $216.00 |
| 82785 | <1% | 16 | $208.98 | |
| 84155 | <1% | 98 | $206.50 | |
| 85045 | <1% | 84 | $199.69 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,145 | $194.32 |
| 76376 | <1% | 183 | $171.36 | |
| 88302 | <1% | 28 | $170.89 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 4,056 | $167.72 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,549 | $165.94 |
| 82140 | <1% | 65 | $160.71 | |
| 98940 | <1% | 628 | $160.33 | |
| 86141 | <1% | 14 | $156.09 | |
| J3486 | Injection, ziprasidone mesylate, 10 mg | <1% | 306 | $153.42 |
| 90662 | <1% | 17 | $153.01 | |
| Q3014 | Telehealth originating site facility fee | <1% | 28 | $152.55 |
| J2704 | Injection, propofol, 10 mg | <1% | 6,020 | $147.16 |
| 80177 | <1% | 27 | $141.16 | |
| 76827 | <1% | 15 | $136.80 | |
| 83527 | <1% | 13 | $128.40 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 463 | $125.34 |
| 94010 | <1% | 14 | $125.31 | |
| 71101 | <1% | 13 | $124.07 | |
| 87329 | <1% | 16 | $120.16 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 10,406 | $120.01 |
| 86695 | <1% | 39 | $116.71 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 1,287 | $107.85 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 139 | $103.31 |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 932 | $99.37 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,406 | $95.65 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 7,963 | $80.13 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 461 | $78.43 |
| 85300 | <1% | 12 | $78.29 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 380 | $74.58 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,050 | $73.51 |
| 82952 | <1% | 30 | $71.50 | |
| 89055 | <1% | 29 | $70.03 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 125 | $53.72 |
| 82977 | <1% | 14 | $45.18 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 392 | $44.27 |
| J1815 | Injection, insulin, per 5 units | <1% | 806 | $38.61 |
| 73060 | <1% | 12 | $37.15 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,495 | $32.78 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 280 | $32.35 |
| 84145 | <1% | 108 | $29.22 | |
| 73600 | <1% | 12 | $28.37 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,791 | $27.25 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,146 | $20.23 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,809 | $19.79 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 219 | $14.58 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 39 | $10.81 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 59 | $8.91 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 270 | $8.89 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 627 | $8.47 |
| 84075 | <1% | 15 | $7.59 | |
| 88300 | <1% | 24 | $6.54 | |
| 84460 | <1% | 13 | $6.32 | |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 836 | $5.31 |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 13 | $5.26 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 34 | $5.19 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 829 | $4.43 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 415 | $4.25 |
| 82040 | <1% | 15 | $2.46 | |
| J2800 | Injection, methocarbamol, up to 10 ml | <1% | 31 | $2.45 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 207 | $1.82 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 65 | $1.39 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 14 | $0.74 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 101 | $0.63 |
| 3008F | <1% | 66 | $0.63 | |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 29 | $0.62 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 199 | $0.48 |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 57 | $0.24 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 43 | $0.19 |
| A4649 | Surgical supply; miscellaneous | <1% | 922 | $0.15 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 239 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 343 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 51 | $0.00 |
| E0114 | Crutches underarm, other than wood, adjustable or fixed, pair, with pads, tips and handgrips | 0% | 15 | $0.00 |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | 0% | 162 | $0.00 |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | 0% | 15 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 53 | $0.00 |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | 0% | 48 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 16 | $0.00 |
| A4364 | Adhesive, liquid or equal, any type, per oz | 0% | 163 | $0.00 |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 0% | 29 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 18 | $0.00 |
| 95806 | 0% | 15 | $0.00 | |
| 99496 | 0% | 14 | $0.00 | |
| 99417 | Prolong home eval add 15m | 0% | 50 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 18 | $0.00 |
| J1836 | Injection, metronidazole, 10 mg | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialOBRIEN, KATHLEEN (DIRECTOR OF THIRD PARTY REIMBURSEME)
Parent organizationUNITED HEALTH SERVICES INC